Red Biotechnology Market Share Analysis Report, 2023-2032
The global red biotechnology market size was exhibited at USD 516.19 billion in 2022 and is projected to hit around USD 1,426.55 billion by 2032, growing at a CAGR of 10.7% during the forecast period 2023 to 2032.
Key Pointers:
Red Biotechnology Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 571.42 Billion |
|
Market Size by 2032 |
USD 1,426.55 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 10.7% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Product, End-user, |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
Merck KGaA; F. Hoffmann-La Roche AG; Pfizer Inc.; Regeneron Pharmaceuticals; Inc.; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; Gilead Sciences; Biogen Inc.; Amgen Inc.; Celgene Corporation |
Red biotechnology has emerged as a most dynamic fields in terms of innovation in past few years. With increasing burden of chronic illnesses such as cancers, genetic disorders, diabetes, and many more, the demand for vaccines, monoclonal antibodies, gene therapies, and cell therapies has grown significantly. Robust pipeline is also expected to propel the growth of red biotechnology market on account of number of expected regulatory approvals in coming years.
COVID- 19 pandemic also had a positive impact on the global market. The approval of various vaccines for management of the virus injected huge revenues within the market place. Similarly enormous number of research studies done for mapping the virus and formulating the vaccine resulted in an increased demand for antibodies, recombinant proteins, enzymes, and many more. For instance, in May 2022, Bharat Biotech received a funding of USD 19 million from Coalition for Epidemic Preparedness Innovations to develop variant proof vaccine against the COVID-19 virus. The pandemic also marked entry of huge number of startups pertaining to biotechnology space creating new market opportunities in emerging countries.
The biotechnology industry is being impacted by Artificial Intelligence (AI), which is important for many processes involved in creating alternative treatments. In the process of developing new medications, artificial intelligence and machine learning are routinely used now. Machine learning makes it easier to find small compounds with medicinal potential based on known target architectures. Increasing adoption of AI in clinical and preclinical studies is expected to reduce the time required to carry out these studies, which in turn is expected to increase the demand for red biotechnology subsets in coming years.
Products Insights
Monoclonal antibodies held the major share of the red biotechnology market with 43.9% in 2022. The rising prevalence of chronic diseases such as cardiovascular disease, cancer, etc. is increasing the demand for biologics, which is expected to serve as a key factor driving the segment's growth. Furthermore, the COVID-19 pandemic has fueled the development of several mAbs directed against the SARS-CoV-2 virus, which has increased market expansion prospects. The mAbs are a promising alternative for COVID-19 mitigation due to their safety and effectiveness, several of these antibodies have received emergency use authorizations from the U.S. FDA.
Gene therapy products are likely to witness the fastest growth in the market. It is expected to expand at a CAGR of 24.4% between 2023 and 2032. The growth can be attributed to factors such as the expansion of gene delivery technologies and advanced therapies, as well as the development of progressive competition among major market players focused on the commercialization of their therapies. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products are in development, including genetically modified cell therapies and CAR T-cell therapies.
Application Insights
The creation of vaccines, such as those that include the DPT, Hepatitis A, Hepatitis B, and polio vaccines and are expected to be administered as vaccinations, is one of the many areas of medicine in which red biotechnology assumes overwhelming significance. Tissue engineering, cancer research, the production of biochips, and other fields benefit from this technology.
Additionally, gene therapy as an application segment would see the highest growth rate due to the extensive research being done to enhance therapeutics for the treatment of the various genetic defects responsible for rare diseases.
Different sectors of medicine in which red biotechnology undertakes excessive prominence are the fabrication of combination vaccines including combined with Hepatitis B, DPT, Hepatitis A, and polio vaccine which is intended to be vaccinated. Further, red biotechnology is advantageous in the arena of poultry farming and veterinary science. Additional spaces where this technology is beneficial are in the arenas of cancer research, tissue engineering, biochips manufacturing and others. Different application segments analyzed under red biotechnology report include gene therapy, biopharmaceutical production, genetic testing and pharmacogenomics. Among all, gene therapy application segment is anticipated to record highest growth rate on account of proliferating research for the improvement of therapeutics to treat numerous genetic disorders accountable for rare sicknesses.
End-user Insights
Pharmaceutical & biotechnology companies are expected to account for the largest market share in 2022. The segment contributed 45.11% of revenues in 2022. Pharmaceutical and biotechnology companies are dealing with a variety of challenging trends. The global demand for COVID-19 vaccines and therapeutics is increasing rapidly, placing an added burden on the industry. The company's ability to find an innovative way to provide COVID-19 vaccines while still meeting overall demand is remarkable, but rising global demand remains a significant long-term challenge for the industry. These businesses are experiencing a wave of innovation, from new treatment modalities to advanced analytics, smart machines, and digital connectivity.
CMOs & CROs is the fastest-growing sub-segment. It is expected to expand at a CAGR of 12.9% between 2023 and 2032. The increasing investment in the biotechnology industry by prominent players to enhance their efficiency and productivity has driven biopharmaceutical manufacturers to increase their focus on outsourcing services. Mergers and acquisitions allow CMOs to offer inclusive bioprocessing services, making CMOs/CROs a feasible option for rapid product launches. The market for CMOs and CROs is still in its early stages, but the introduction of novel therapeutics, new bioprocessing tools, and product priority shifts in the bio/pharmaceutical industry has increased the pressure on contract bio manufacturers.
Regional Insights
North America accounted for the largest share of 38.09% in the market in 2022. The large share is mainly attributed to an increase in R&D activities and technological advancements in the field of biotechnology. The U.S. is among the key markets in the biotechnology industry. Major factors such as developed infrastructure, and the rise in the incidence of various diseases are driving the market growth in the region. For instance, In June 2022, a gene therapy developed by Bluebird Bio received support from advisors and is currently being evaluated by the U.S. FDA for the treatment of cerebral adrenoleukodystrophy in patients under the age of 18.
Asia Pacific will likely emerge as the fastest region during the study period. The emerging economies of Asia Pacific countries such as India, and China are majorly contributing to the growth of this region. These countries are involved into private-public collaborations, and government initiatives that are propelling the growth of Asian market.
Some of the prominent players in the Red Biotechnology Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Red Biotechnology market.
By Product Type
By Application
By End-user
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Red Biotechnology Market
5.1. COVID-19 Landscape: Red Biotechnology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Red Biotechnology Market, By Product
8.1. Red Biotechnology Market, by Product Type, 2023-2032
8.1.1. Gene Recombinant Drugs
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Human Vaccines
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Blood Products
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Personalized Medicines
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Diagnostics Reagents
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Red Biotechnology Market, By Application
9.1. Red Biotechnology Market, by Application, 2023-2032
9.1.1. Pharmacogenomics
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Biopharmaceutical Production
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Gene Therapy
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Genetic Testing
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Red Biotechnology Market, By End User
10.1. Red Biotechnology Market, by End User, 2023-2032
10.1.1. Research Institutes
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. CMOs & CROs
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Biopharmaceutical Industries
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Red Biotechnology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End User (2020-2032)
Chapter 12. Company Profiles
12.1. Hoffmann-La Roche, Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Merck KGaA
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Regeneron Pharmaceuticals, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Biogen Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. AstraZeneca Plc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Takeda Pharmaceutical Company Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Gilead Sciences, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. CELGENE CORPORATION
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers